Prestige Biologics, a Contract Development and Manufacturing Organization (CDMO) specializing in biopharmaceuticals, announced the establishment of a strategic partnership with Aurigene Pharmaceutical Services Limited (APSL), a wholly owned step-down subsidiary company of Dr. Reddy's Laboratories Limited, through the signing of a non-binding Memorandum of Understanding (MoU).

The MoU, which is subject to a Definitive Agreement, will oversee collaborative efforts between Prestige Biologics and APSL to bring in a comprehensive set of services and capabilities towards meeting the CDMO needs of biologics-focused companies.

'We are delighted to announce our strategic partnership with Aurigene Pharmaceutical Services Limited,' stated Duk Hoon Hyun, CEO of Prestige Biologics. 'Prestige Biologics' global prominence in the CDMO market, coupled with Aurigene's pharmaceutical expertise in R&D services, will create an end-to-end service capability in the Biologics CRDMO segment through this collaboration, offering cell line development to large-scale manufacturing services for global Biologics customers.'

Aurigene Pharmaceutical Services Limited is a Contract Research, Development and Manufacturing Organization (CRDMO) with end-to-end capabilities across drug discovery, development, and manufacturing of small and large molecules. Dr. Reddy's Laboratories Limited, the parent company of APSL, is a global pharmaceutical company, founded in 1984, with four decades of expertise in pharmaceutical development, and a global commercial network. Prestige Biologics operates production facilities based in South Korea, with a manufacturing capacity of 154,000 litres, making Prestige Biologics one of the top 10 global CDMO companies working with animal cell culture.

Contact:

Tel: +65 6924 6535

(C) 2023 Electronic News Publishing, source ENP Newswire